Cannabis Science (NASD OTC: CBIS),
a pioneering U.S. Biotech Company developing pharmaceutical products for
global public health challenges, is pleased to announce preclinical
investigations being initiated in Europe for Squamous/Basal Cell
carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity
utilizing cannabinoids that have been demonstrated in recent studies to
significantly affect tumor necrosis.
The company is entertaining entrance into a number of agreements with
academic and private sector clinical research organizations that will
facilitate initial studies to demonstrate scientific merit of CSTATI-1
and CS-S/BCC-1 that will predictably translate to human studies within
the coming year, as clinical options for this patient population remain
limited and the etiology of both aggressive squamous/basel cell
carcinomas and Kaposi's sarcoma is poor in immune compromised
populations, comparative to other skin cancers.
"To match our U.S. efforts, we are aggressively pursuing institutional
investigations abroad to take advantage of the significant expertise
demonstrated in many academic research centers on cannabinoids to
further our clinical investigation platform," said Dr. Robert Melamede,
President & CEO of Cannabis Science Inc., "we expect to generate from
these collaborations a robust portfolio of preclinical data that
supports the wide range of our scientific premises on the utility of
cannabinoids for aggressive cancers for patients in desperate need of
innovative clinical alternatives."
The Company will update the public and its shareholders of the progress
as peer-reviewed publication of the results of these preclinical
investigations are made public.
Lower grades for students who use both tobacco and cannabis, California survey reveals